AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.

The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...

The following is a summary of “A predictive model based on the gut microbiota improves the diagnostic effect in patients with ...

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo; Achieved statistical significance ...

Patients with late-onset rheumatoid arthritis experienced greater functional impairment over 5 years, compared against those with younger-onset disease.

Roivant Sciences Ltd. ( ($ROIV) ) has released its Q3 earnings. Here is a breakdown of the information Roivant Sciences Ltd. presented to its ...

Higher low-carbohydrate diet (LCD) scores, characterized by reduced carbohydrate intake and increased protein consumption, are associated with a lower likelihood of rheumatoid arthritis (RA) among ...

Turmeric shots are a wellness drink that may offer many health benefits for their antioxidant and anti-inflammatory effects, ...